QQ客服 官方微博 反馈留言

浏览/检索结果: 共3条，第1-3条 帮助 已选(0)清除 条数/页：5101520253035404550556065707580859095100   排序方式：请选择发表日期升序发表日期降序作者升序作者降序提交时间升序提交时间降序题名升序题名降序 Randomised study of evolocumab in patients with type 2 diabetes and dyslipidaemia on background statin: Primary results of the BERSON clinical trial 期刊论文 DIABETES OBESITY & METABOLISM, 2019, 卷号: 21, 期号: 6 作者:  Lorenzatti, Alberto J.;  Eliaschewitz, Freddy G.;  Chen, Yundai;  Lu, Juming;  Baass, Alexis 收藏  |  浏览/下载：23/0  |  提交时间：2019/12/05 dyslipidaemia  evolocumab  hyperlipidaemia  phase 3  type 2 diabetes   Randomized study of evolocumab in patients with type 2 diabetes and dyslipidaemia on background statin: Pre-specified analysis of the Chinese population from the BERSON clinical trial 期刊论文 DIABETES OBESITY & METABOLISM, 2019, 卷号: 21, 期号: 6 作者:  Chen, Yundai;  Yuan, Zuyi;  Lu, Juming;  Eliaschewitz, Freddy G.;  Lorenzatti, Alberto J. 收藏  |  浏览/下载：38/0  |  提交时间：2019/12/05 dyslipidaemia  evolocumab  hyperlipidaemia  phase 3  type 2 diabetes   Rationale and design of a randomized study to assess the efficacy and safety of evolocumab in patients with diabetes and dyslipidemia: The BERSON clinical trial 期刊论文 CLINICAL CARDIOLOGY, 2018, 卷号: 41, 期号: 9 作者:  Lorenzatti, Alberto J.;  Eliaschewitz, Freddy G.;  Chen, Yundai;  Fialkow, Jonathan;  Lu, Juming 收藏  |  浏览/下载：14/0  |  提交时间：2019/12/05 diabetes  diabetic dyslipidemia  dyslipidemia  hypercholesterolemia  monoclonal antibody  PCSK9  PCSK9 inhibitor